SNDX
Syndax Pharmaceuticals, Inc.·Healthcare
19.94
0.860%(+0.17)
Market ClosedLast Updated: — ET
52W L: $8.5952W H: $25.59
SNDX NEWS
globenewswire.com
2d ago
Syndax Announces Four Revuforj® (revumenib) Abstracts Accepted for ASCO 2026, Including an Oral Presentation of Post-Transplant Data
– Oral presentation will highlight favorable outcomes observed among 21 adults and children with KMT2Ar, NPM1m, or NUP98r acute leukemia who received revumenib post-transplant –
globenewswire.com
3d ago
Syndax Announces Participation in Upcoming Investor Conferences
NEW YORK, May 20, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, as well as members of the Syndax management team, will participate in the following upcoming investor conferences:
globenewswire.com
May 12
Syndax Highlights 12 Revuforj® (revumenib) Abstracts Accepted for EHA 2026, Advancing Leadership in Menin Inhibition
– Abstracts highlight strong revumenib activity across the acute leukemia treatment continuum and multiple genetic subtypes – – New real-world data show compelling outcomes and favorable tolerability with revumenib monotherapy and combination use – – Two abstracts highlight encouraging results with revumenib in the post-transplant setting – – Frontline and R/R revumenib combination data show deep responses, robust transplant rates, and favorable tolerability – – Encouraging activity observed with revumenib in R/R NUP98r acute leukemia – NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today highlighted the release of 12 Revuforj® (revumenib) abstracts on the European Hematology Association (EHA) website in advance of the EHA 2026 Congress, taking place June 11-14, 2026, in Stockholm, Sweden. “The breadth of data accepted for presentation at EHA underscores the strength of revumenib's clinical profile, with activity observed across the acute leukemia treatment continuum in KMT2Ar, NPM1m, and NUP98r acute leukemias,” said Nick Botwood, MBBS, Head of Research & Development and Chief Medical Officer at Syndax.
globenewswire.com
May 6
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on May 1, 2026, the Company granted inducement awards to purchase up to 162,100 shares of common stock to eight new employees under the Company's 2023 Inducement Plan. The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.
seekingalpha.com
Apr 30
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
Syndax Pharmaceuticals, Inc. (SNDX) Q1 2026 Earnings Call Transcript
zacks.com
Apr 30
Syndax Pharmaceuticals (SNDX) Reports Q1 Loss, Misses Revenue Estimates
Syndax Pharmaceuticals (SNDX) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to a loss of $0.98 per share a year ago.
